Kanglong Huacheng: Commercial production of preparation workshop receives orders from international pharmaceutical companies, and the small molecule CDMO gross profit margin is expected to increase.

Kanglong Huacheng released an announcement of the investors relations activity record. The construction of the formulation commercial production workshop located in the Beijing Second Park was completed, and in the first quarter of 2026, the company signed a strategic cooperation agreement with a large international pharmaceutical company to provide commercial production services for its first registered oral small molecule GLP-1 receptor agonist. During the reporting period, the company's newly signed order amount increased by over 14% year-on-year, with over 950 new clients and over 3,300 active clients. Revenue from the top 20 global pharmaceutical companies increased by 29.4% year-on-year. The small molecule CDMO service involves 1,102 drug molecules or intermediates, with 34 projects in the process validation and commercialization stages and 47 projects in the Phase III clinical stage. As the revenue scale of the small molecule CDMO segment grows and the project structure advances to the later stages, the gross profit margin of the small molecule CDMO service is expected to increase year-on-year compared to 2025. The company is expected to maintain steady growth in 2026, with the new signed orders showing a growth momentum since the beginning of the year, and the revenue from clinical research services is expected to continue growing.